|
1
|
Buonaguro L, Petrizzo A, Tagliamonte M,
Tornesello ML and Buonaguro FM: Challenges in cancer vaccine
development for hepatocellular carcinoma. J Hepatol. 59:897–903.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ikeda K, Arase Y, Saitoh S, Kobayashi M,
Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N and Kumada H:
Interferon beta prevents recurrence of hepatocellular carcinoma
after complete resection or ablation of the primary tumor-A
prospective randomized study of hepatitis C virus-related liver
cancer. Hepatology. 32:228–232. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kubo S, Nishiguchi S, Hirohashi K, Tanaka
H, Shuto T and Kinoshita H: Randomized clinical trial of long-term
outcome after resection of hepatitis C virus-related hepatocellular
carcinoma by postoperative interferon therapy. Br J Surg.
89:418–422. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shiratori Y, Shiina S, Teratani T, Imamura
M, Obi S, Sato S, Koike Y, Yoshida H and Omata M: Interferon
therapy after tumor ablation improves prognosis in patients with
hepato-cellular carcinoma associated with hepatitis C virus. Ann
Intern Med. 138:299–306. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tabb MM, Sun A, Zhou C, Grün F, Errandi J,
Romero K, Pham H, Inoue S, Mallick S, Lin M, et al: Vitamin K2
regulation of bone homeostasis is mediated by the steroid and
xenobiotic receptor SXR. J Biol Chem. 278:43919–43927. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shiraki M, Shiraki Y, Aoki C and Miura M:
Vitamin K2 (mena-tetrenone) effectively prevents fractures and
sustains lumbar bone mineral density in osteoporosis. J Bone Miner
Res. 15:515–521. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Otsuka M, Kato N, Shao RX, Hoshida Y,
Ijichi H, Koike Y, Taniguchi H, Moriyama M, Shiratori Y, Kawabe T,
et al: Vitamin K2 inhibits the growth and invasiveness of
hepatocellular carcinoma cells via protein kinase A activation.
Hepatology. 40:243–251. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Azuma K, Urano T, Ouchi Y and Inoue S:
Vitamin K2 suppresses proliferation and motility of hepatocellular
carcinoma cells by activating steroid and xenobiotic receptor.
Endocr J. 56:843–849. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamamoto T, Nakamura H, Liu W, Cao K,
Yoshikawa S, Enomoto H, Iwata Y, Koh N, Saito M, Imanishi H, et al:
Involvement of hepatoma-derived growth factor in the growth
inhibition of hepatocellular carcinoma cells by vitamin K(2). J
Gastroenterol. 44:228–235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sakon M, Monden M, Gotoh M, Kobayashi K,
Kanai T, Umeshita K, Endoh W and Mori T: The effects of vitamin K
on the generation of des-gamma-carboxy prothrombin (PIVKA-II) in
patients with hepatocellular carcinoma. Am J Gastroenterol.
86:339–345. 1991.PubMed/NCBI
|
|
12
|
Koike Y, Shiratori Y, Sato S, Obi S,
Teratani T, Imamura M, Yoshida H, Shiina S and Omata M:
Des-gamma-carboxy prothrombin as a useful predisposing factor for
the development of portal venous invasion in patients with
hepatocellular carcinoma: A prospective analysis of 227 patients.
Cancer. 91:561–569. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoshida T, Miyazawa K, Kasuga I, Yokoyama
T, Minemura K, Ustumi K, Aoshima M and Ohyashiki K: Apoptosis
induction of vitamin K2 in lung carcinoma cell lines: The
possibility of vitamin K2 therapy for lung cancer. Int J Oncol.
23:627–632. 2003.PubMed/NCBI
|
|
14
|
Enomoto M, Tsuchida A, Miyazawa K,
Yokoyama T, Kawakita H, Tokita H, Naito M, Itoh M, Ohyashiki K and
Aoki T: Vitamin K2-induced cell growth inhibition via autophagy
formation in cholangiocellular carcinoma cell lines. Int J Mol Med.
20:801–808. 2007.PubMed/NCBI
|
|
15
|
Riaz IB, Riaz H, Riaz T, Rahman S, Amir M,
Badshah MB and Kazi AN: Role of vitamin K2 in preventing the
recurrence of hepatocellular carcinoma after curative treatment: A
meta-analysis of randomized controlled trials. BMC Gastroenterol.
12:170–179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoshida H, Shiratori Y, Kudo M, Shiina S,
Mizuta T, Kojiro M, Yamamoto K, Koike Y, Saito K, Koyanagi N, et
al: Effect of vitamin K2 on the recurrence of hepatocellular
carcinoma. Hepatology. 54:532–540. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Osna NA and Donohue TM Jr:
CYP2E1-catalyzed alcohol metabolism: Role of oxidant generation in
interferon signaling, antigen presentation and autophagy. Subcell
Biochem. 67:177–197. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schattenberg JM, Wang Y, Rigoli RM, Koop
DR and Czaja MJ: CYP2E1 overexpression alters hepatocyte death from
menadione and fatty acids by activation of ERK1/2 signaling.
Hepatology. 39:444–455. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang X, Lu Y and Cederbaum AI: Induction
of cytochrome P450 2E1 increases hepatotoxicity caused by Fas
agonistic Jo2 antibody in mice. Hepatology. 42:400–410. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Martini R, Ingelman-Sundberg M and Murray
M: Pretranslational and post-translational regulation of rat
hepatic CYPs 3A2 and 2E1 by disulfiram. Biochem Pharmacol.
54:1323–1329. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wall KL and Crivello J: Chlorzoxazone
metabolism by winter flounder liver microsomes: Evidence for
existence of a CYP2E1-like isoform in teleosts. Toxicol Appl
Pharmacol. 151:98–104. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bansal S, Anandatheerthavarada HK, Prabu
GK, Milne GL, Martin MV, Guengerich FP and Avadhani NG: Human
cytochrome P450 2E1 mutations that alter mitochondrial targeting
efficiency and susceptibility to ethanol-induced toxicity in
cellular models. J Biol Chem. 288:12627–12644. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Osna NA, Clemens DL and Donohue TM Jr:
Interferon gamma enhances proteasome activity in recombinant Hep G2
cells that express cytochrome P4502E1: Modulation by ethanol.
Biochem Pharmacol. 66:697–710. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu H, Cai P, Clemens DL, Jerrells TR,
Ansari GA and Kaphalia BS: Metabolic basis of ethanol-induced
cytotoxicity in recombinant HepG2 cells: Role of nonoxidative
metabolism. Toxicol Appl Pharmacol. 216:238–247. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wilfred de Alwis NM and Day CP: Genetics
of alcoholic liver disease and nonalcoholic fatty liver disease.
Semin Liver Dis. 27:44–54. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sasaki N, Kusano E, Takahashi H, Ando Y,
Yano K, Tsuda E and Asano Y: Vitamin K2 inhibits
glucocorticoid-induced bone loss partly by preventing the reduction
of osteoprotegerin (OPG). J Bone Miner Metab. 23:41–47. 2005.
View Article : Google Scholar
|
|
27
|
Matsumoto K, Okano J, Nagahara T and
Murawaki Y: Apoptosis of liver cancer cells by vitamin K2 and
enhancement by MEK inhibition. Int J Oncol. 29:1501–1508.
2006.PubMed/NCBI
|
|
28
|
Yaguchi M, Miyazawa K, Katagiri T,
Nishimaki J, Kizaki M, Tohyama K and Toyama K: Vitamin K2 and its
derivatives induce apoptosis in leukemia cells and enhance the
effect of all-trans retinoic acid. Leukemia. 11:779–787. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yokoyama T, Miyazawa K, Naito M, Toyotake
J, Tauchi T, Itoh M, Yuo A, Hayashi Y, Georgescu MM, Kondo Y, et
al: Vitamin K2 induces autophagy and apoptosis simultaneously in
leukemia cells. Autophagy. 4:629–640. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang CS, Yoo JS, Ishizaki H and Hong JY:
Cytochrome P450IIE1: Roles in nitrosamine metabolism and mechanisms
of regulation. Drug Metab Rev. 22:147–159. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yan QG, Shi JG, Zhang F, Zhao QT, Pang XW,
Chen R, Hu PZ, Li QL, Wang Z and Huang GS: Overexpression of CYP2E1
enhances sensitivity of hepG2 cells to fas-mediated cytotoxicity.
Cancer Biol Ther. 7:1280–1287. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hirose Y, Naito Z, Kato S, Onda M and
Sugisaki Y: Immuno-histochemical study of CYP2E1 in hepatocellular
carcinoma carcinogenesis: Examination with newly prepared
anti-human CYP2E1 antibody. J Nippon Med Sch. 69:243–251. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Man XB, Tang L, Qiu XH, Yang LQ, Cao HF,
Wu MC and Wang HY: Expression of cytochrome P4502E1 gene in
hepato-cellular carcinoma. World J Gastroenterol. 10:1565–1568.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ho JC, Cheung ST, Leung KL, Ng IO and Fan
ST: Decreased expression of cytochrome P450 2E1 is associated with
poor prognosis of hepatocellular carcinoma. Int J Cancer.
111:494–500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Caro AA and Cederbaum AI: Oxidative
stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol
Toxicol. 44:27–42. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen Q and Cederbaum AI: Cytotoxicity and
apoptosis produced by cytochrome P450 2E1 in Hep G2 cells. Mol
Pharmacol. 53:638–648. 1998.PubMed/NCBI
|
|
37
|
Castillo T, Koop DR, Kamimura S,
Triadafilopoulos G and Tsukamoto H: Role of cytochrome P-450 2E1 in
ethanol-, carbon tetrachloride- and iron-dependent microsomal lipid
peroxidation. Hepatology. 16:992–996. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Morimoto M, Zern MA, Hagbjörk AL,
Ingelman-Sundberg M and French SW: Fish oil, alcohol, and liver
pathology: Role of cytochrome P450 2E1. Proc Soc Exp Biol Med.
207:197–205. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nanji AA, Zhao S, Sadrzadeh SM, Dannenberg
AJ, Tahan SR and Waxman DJ: Markedly enhanced cytochrome P450 2E1
induction and lipid peroxidation is associated with severe liver
injury in fish oil-ethanol-fed rats. Alcohol Clin Exp Res.
18:1280–1285. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Robertson G, Leclercq I and Farrell GC:
Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450
enzymes and oxidative stress. Am J Physiol Gastrointest Liver
Physiol. 281:G1135–G1139. 2001.PubMed/NCBI
|
|
41
|
Gonzalez FJ: The 2006 Bernard B. Brodie
Award Lecture. Cyp2e1. Drug Metab Dispos. 35:1–8. 2007. View Article : Google Scholar
|
|
42
|
Woodcroft KJ, Hafner MS and Novak RF:
Insulin signaling in the transcriptional and post-transcriptional
regulation of CYP2E1 expression. Hepatology. 35:263–273. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Johansson I, Lindros KO, Eriksson H and
Ingelman-Sundberg M: Transcriptional control of CYP2E1 in the
perivenous liver region and during starvation. Biochem Biophys Res
Commun. 173:331–338. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lagadic-Gossmann D, Lerche C, Rissel M,
Joannard F, Galisteo M, Guillouzo A and Corcos L: The induction of
the human hepatic CYP2E1 gene by interleukin 4 is transcriptional
and regulated by protein kinase C. Cell Biol Toxicol. 16:221–233.
2000. View Article : Google Scholar : PubMed/NCBI
|
